Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. EVMN
EVMN logo

EVMN

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

EVMN News

Evommune Biotech Stock Shows Huge Potential

7h agoFool

Evommune Reports Increased Losses in Q4

4d agoNASDAQ.COM

Evommune, Inc. Reports FY 2025 Financial Results

4d agoseekingalpha

Benzinga Stock Whisper Index Analysis

Feb 15 2026Benzinga

Evommune Secures $125M in Private Placement Agreement

Feb 13 2026seekingalpha

Evommune Enters Private Placement Agreement for $125 Million

Feb 13 2026Businesswire

Evommune Secures $125 Million in Private Placement

Feb 13 2026Newsfilter

Evommune Shares Drop on Profit-Taking After 70% Surge

Feb 12 2026Benzinga

EVO301 Clinical Trial Achieves Significant Results

Feb 10 2026Benzinga

Datadog Beats Earnings Estimates, Shares Surge 16.3%

Feb 10 2026Benzinga

Evommune Shares Surge Over 50% After Mid-Stage Trial Success for EVO301

Feb 10 2026seekingalpha

U.S. Stocks Mixed in Morning Trading

Feb 10 2026Benzinga

Evommune's Atopic Dermatitis Drug Trial Success Boosts Shares

Feb 10 2026stocktwits

EVO301 Clinical Trial Achieves Positive Results

Feb 10 2026Newsfilter

Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly

Jan 09 2026renaissancecapital

Analysts Adjust Ratings on Wealthfront and Spire Global with Price Targets

Jan 06 2026Benzinga